SIGA TECHNOLOGIES INC. - COMMON STOCK
6.4800
22-十一月-24 16:44:58
15 分钟延时
股票
+0.2100
+3.35%
今日范围
6.3400 - 6.5800
ISIN
N/A
来源
NASDAQ
-
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
15 7月 2022 07:30:00 条件 Nasdaq GlobeNewswire
-
12 7月 2022 16:15:00 条件 Nasdaq GlobeNewswire
-
SIGA Technologies Receives Approval from UK for Tecovirimat
08 7月 2022 07:30:00 条件 Nasdaq GlobeNewswire
-
SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
23 6月 2022 08:00:01 条件 Nasdaq GlobeNewswire
-
SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022
22 6月 2022 10:13:44 条件 Nasdaq GlobeNewswire
-
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
19 5月 2022 07:30:00 条件 Nasdaq GlobeNewswire
-
12 5月 2022 16:05:01 条件 Nasdaq GlobeNewswire
-
SIGA Reports Financial Results for Three Months Ended March 31, 2022
05 5月 2022 16:05:02 条件 Nasdaq GlobeNewswire
-
SIGA Declares Special Dividend of $0.45 Per Share
05 5月 2022 07:30:01 条件 Nasdaq GlobeNewswire
-
28 4月 2022 16:05:02 条件 Nasdaq GlobeNewswire
-
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021
03 3月 2022 16:05:01 条件 Nasdaq GlobeNewswire
-
SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials
02 3月 2022 07:30:00 条件 Nasdaq GlobeNewswire
-
24 2月 2022 10:27:12 条件 Nasdaq GlobeNewswire
-
SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech
25 1月 2022 07:30:00 条件 Nasdaq GlobeNewswire
-
18 1月 2022 07:30:00 条件 Nasdaq GlobeNewswire
-
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
10 1月 2022 07:30:00 条件 Nasdaq GlobeNewswire
-
SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®
01 12月 2021 09:55:02 条件 Nasdaq GlobeNewswire
-
16 11月 2021 08:30:00 条件 Nasdaq GlobeNewswire
-
SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021
04 11月 2021 16:05:01 条件 Nasdaq GlobeNewswire
-
28 10月 2021 16:15:00 条件 Nasdaq GlobeNewswire